# Gamma-2 Herpesviruses as Vaccine Vectors for AIDS

> **NIH NIH R37** · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · 2021 · $583,538

## Abstract

Results of both monkey and human trials have highlighted the difficulties in achieving vaccine protection
against SIV and HIV. Persistent, recombinant herpesviruses are being used in monkeys to try to match the
degree of protection that can be achieved with live attenuated strains of SIV. Results to date have been
promising but the absence of anti-Env antibody responses from the recombinant herpesviruses has been a
glaring deficiency. The proposed experiments will overcome this deficiency and allow full testing of the
promise of this approach.

## Key facts

- **NIH application ID:** 10071122
- **Project number:** 5R37AI063928-15
- **Recipient organization:** UNIVERSITY OF MIAMI SCHOOL OF MEDICINE
- **Principal Investigator:** Ronald C Desrosiers
- **Activity code:** R37 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $583,538
- **Award type:** 5
- **Project period:** 2005-03-15 → 2022-11-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10071122

## Citation

> US National Institutes of Health, RePORTER application 10071122, Gamma-2 Herpesviruses as Vaccine Vectors for AIDS (5R37AI063928-15). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10071122. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*